Bio-Techne Gross Profit

The latest gross profit for TECH is $790M as of March 2026. That compares with $830M in the prior-year period — down 5.7% year over year. That is below the Healthcare sector average of $64B. Investors often review this figure alongside Bio-Techne's historical trend and sector peers before judging valuation or financial health.

Over the past year, TECH's gross profit moved from $830M to $790M — a 5.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bio-Techne's operating scale or balance-sheet position.

Against Healthcare companies, TECH currently prints $790M for gross profit, while the sector average sits near $64B. That is roughly 98.8% below the sector mean. Large gaps often invite a closer look at Bio-Techne's growth, margins, and balance sheet.

A gross profit figure of $790M for TECH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $64B. Explore the charts below for those layers of context.

After noting TECH's gross profit ($790M), review year-over-year change from $830M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.